Navigation Links
Helix BioPharma Corp. Announces Fiscal 2008 Results
Date:10/28/2008

AURORA, Ontario, Oct. 28 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP") today announced financial results for the year ended July 31, 2008.

During the 2008 fiscal year, the Company continued to make progress with its development initiatives for its lead drug candidates, L-DOS47 and Topical Interferon Alpha-2b. The following are selected highlights during the 2008 fiscal year and subsequent to year-end.

KEY HIGHLIGHTS

-- DOS47/L-DOS47

-- Signed an agreement with a fill/finish provider to perform vial

packaging of L-DOS47 for clinical testing.

-- Signed an agreement with a company specializing in lyophilization

(freeze-drying) to develop the L-DOS47 vial packaging format

-- Signed a second, more definitive agreement with our L-DOS47 active

drug substance and bulk drug product manufacturer to further scale

up the GMP production process in preparation for clinical testing.

-- Awarded a second U.S. patent protecting the use of targeted

DOS47-based therapeutics, such as L-DOS47, in combination

therapeutic regimens with certain chemotherapeutic agents

-- Topical Interferon Alpha-2b

-- Received regulatory approval to open sites in Germany for the

ongoing Phase II clinical trial in patients with ano-genital warts.

-- Conducted meetings with German regulators as a preliminary step

towards filing a CTA for a planned, large, randomized,

placebo-controlled, double-blind Phase III European clinical trial

in patients with low-grade cervical lesions.

-- Signed an agreement to further scale up the production of Topical

Interferon Alpha-2b in anticipation of conducting the planned

European Phase III clinical trial in patients with low-grade

cervical lesions, as well as
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Helix Biopharma Closes $11.4 Million Private Placement
2. Helix BioPharma Announces $11.4 Million Private Placement
3. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
4. Sigma-Aldrich Announces Collaboration With Metahelix Life Sciences
5. Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008
6. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
7. Helix BioPharma reports Q2 2008 highlights, financial results
8. Helix BioPharma shareholders vote in favour of management
9. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Helix BioPharma announces Q1 2008 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... (PRWEB) December 24, 2014 The report ... at 19.7% by 2019. It also provides a carefully ... strategies and challenges for the market. , Full Copy ... the report, the global market for cell expansion will ... future. It expects this growth to be driven by ...
(Date:12/24/2014)... China Biologic Products, Inc. (NASDAQ: CBPO, ... integrated plasma-based biopharmaceutical company in China ... Shandong Taibang Biological Products Co. Ltd., has received ... Food and Drug Administration (the "CFDA") for its ... in the Company,s public filings, the CFDA inspected ...
(Date:12/24/2014)... 2014 PharmaBoardroom,s new report, ... and available for free download , digs deep into ... growth in the sector today. One area where ... been in developing a homegrown pharmaceutical manufacturing base, even if ... remains some way off. A cursory comparison with neighboring ...
(Date:12/24/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ) ... Application (CTA) with the United Kingdom,s ... approval to initiate clinical trials for the continued development ... on the Company receiving CTA regulatory approval, the Company ... the safety, tolerability and dose escalation of Anatabine Citrate ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... to see is based on molecules in the eye ... to visible light. Now, a new technique for ... molecules to be switched between two different configurations in ... Because the configuration changes are reversible and can be ...
... Bion Environmental,Technologies, Inc. (OTC Bulletin Board: BNET) today ... environmental,treatment technology compared to anaerobic digesters., Anaerobic ... produce energy,from livestock waste since the late 1800s. ... is still based on a biological process that,produces ...
... Premier healthcare,alliance Purchasing Partners division recently announced ... one of 15 winners,chosen for the Pinnacle ... suppliers,representing the top two percent of healthcare ... exceeds the expectations of,Premier and its members ...
Cached Biology Technology:Tethered molecules act as light-driven reversible nanoswitches 2Bion Outlines Differences between its Patented Comprehensive Livestock Environmental Treatment Technology and Anaerobic Digesters 2Bion Outlines Differences between its Patented Comprehensive Livestock Environmental Treatment Technology and Anaerobic Digesters 3Bion Outlines Differences between its Patented Comprehensive Livestock Environmental Treatment Technology and Anaerobic Digesters 4Bion Outlines Differences between its Patented Comprehensive Livestock Environmental Treatment Technology and Anaerobic Digesters 5Bion Outlines Differences between its Patented Comprehensive Livestock Environmental Treatment Technology and Anaerobic Digesters 6Bion Outlines Differences between its Patented Comprehensive Livestock Environmental Treatment Technology and Anaerobic Digesters 7Premier Healthcare Alliance Honors Siemens Healthcare Diagnostics for Excellence in Supplier Performance 2Premier Healthcare Alliance Honors Siemens Healthcare Diagnostics for Excellence in Supplier Performance 3
(Date:12/17/2014)...  Automation is fundamentally transforming the travel experience ... international borders. Over the past decade, ePassports, biometric ... travelers to self process through border control via ... an increasing number of airports, seaports, and land ... to Maxine Most , Principal at Acuity ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... in Spanish . , Pioneering studies ... Robert A. Waterland are helping explain how the foods ... the time of conceptionor what,s known as periconceptional nutritionmay ... her children,s health. In an early study, Waterland ...
... lack of very long chain fatty acids in photoreceptor cells ... an incurable eye disease. But researchers at the University of ... new study that lack of these fatty acids does not ... robs sight from children with the disease must start anew. ...
... mean failure of both summer and winter rains, according to ... The finding contradicts the commonly held belief that a ... monsoon season, and vice versa. The new research ... 1539 to 2008, generally both winter and summer rains were ...
Cached Biology News:Epigenetics mechanism may help explain effects of mom's nutrition on her children's health 2Long-suspected cause of blindness from eye disease disproved 2Monsoon failure key to long droughts in Southwest 2Monsoon failure key to long droughts in Southwest 3
Goat polyclonal to STMN2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: AKTAMAYKEK, corresponding to C terminal amino acids 2-11 of STMN2. Entrez Gene ID: 11075 Swi...
... Goat polyclonal to PAX3 This ... box (PAX) family of transcription factors. Members ... paired box domain and a paired-type homeodomain. ... development. Mutations in paired box gene 3 ...
Mouse monoclonal antibody to RNase L...
Mouse polyclonal antibody to MCFD2 - multiple coagulation factor deficiency 2...
Biology Products: